RHD and fetal erythroblastosis: Although previous studies attempted to identify the burden of HDFN due to a lack of immunoprophylaxis in low income countries [11, 13] to our knowledge, this is the first study to estimate the difference between the annual number of doses of IgG anti-Rh(D) required and those administered at a global level.